Vident Advisory LLC Boosts Stake in Pfizer Inc. $PFE

Key Points

• Vident Advisory LLC significantly increased its stake in Pfizer by 761.7%, now holding 80,414 shares worth approximately $2.04 million.
• Pfizer reported a 10.3% year-over-year revenue growth for the last quarter, achieving revenue of $14.65 billion and earnings per share of $0.78.
• The company recently announced a quarterly dividend of $0.43 per share, with an annualized dividend yield of 7.0%.

Vident Advisory LLC grew its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 761.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 80,414 shares of the biopharmaceutical company's stock after purchasing an additional 71,082 shares during the period. Vident Advisory LLC's holdings in Pfizer were worth $2,038,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in PFE. Brighton Jones LLC increased its stake in Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after acquiring an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC increased its stake in Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after acquiring an additional 2,087 shares during the last quarter. Triumph Capital Management increased its stake in Pfizer by 20.0% during the fourth quarter. Triumph Capital Management now owns 10,283 shares of the biopharmaceutical company's stock worth $273,000 after acquiring an additional 1,717 shares during the last quarter. BIP Wealth LLC increased its stake in Pfizer by 11.1% during the fourth quarter. BIP Wealth LLC now owns 11,853 shares of the biopharmaceutical company's stock worth $314,000 after acquiring an additional 1,180 shares during the last quarter. Finally, Chapman Financial Group LLC bought a new stake in Pfizer during the fourth quarter worth approximately $563,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Stock Performance

Shares of NYSE PFE traded up $0.18 during mid-day trading on Tuesday, hitting $24.94. The stock had a trading volume of 44,247,211 shares, compared to its average volume of 40,145,636. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The company has a 50 day moving average of $24.82 and a two-hundred day moving average of $24.37. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43. The firm has a market cap of $141.77 billion, a PE ratio of 13.26, a PEG ratio of 0.88 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period in the prior year, the company earned $0.60 earnings per share. The firm's revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.9%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio is presently 91.49%.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on PFE shares. Morgan Stanley boosted their target price on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 6th. Jefferies Financial Group boosted their target price on Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research report on Wednesday, May 21st. Berenberg Bank dropped their target price on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research report on Thursday, May 29th. HSBC dropped their target price on Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research report on Monday, May 19th. Finally, Citigroup boosted their target price on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Pfizer presently has an average rating of "Hold" and an average price target of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.